Sandoz biosimilars are manufactured using the same state-of-the-art biological production technologies and quality standards as novel biologics.3 Biosimilar production is carried out on a clinical and commercial scale, using both microbial and cell-culture technologies.4
References: 1. BioProcess International. A decade of microbial fermentation. http://www.bioprocessintl.com/upstream-processing/fermentation/a-decade-of-microbial-fermentation-331179. Published June 1, 2012. Accessed September 7, 2016. 2. Data on File. Manufacturing Manual Version 2.0. Sandoz Inc. Princeton, NJ. 3. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91:405-417. 4. Data on file. S-XBP-1335749. Sandoz Inc. Princeton, NJ. 5. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209-217. doi:10.4161/mabs.3.2.15005. 6. ICIS. Contract biopharm manufacturing stays robust. http://www.icis.com/resources/news/2004/01/16/549775/contract-biopharm-manufacturing-stays-robust/. Published January 16, 2004. Accessed September 7, 2016. 7. Sandoz.com. Sandoz Inaugurates BioInject – a new state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria. https://www.sandoz.com/news/media-releases/sandoz-inaugurates-bioinject-new-state-art-biopharmaceutical-manufacturing. Published September 17, 2015. Accessed October 10, 2016.